CD19 and leukemia: Consistent with previous results, flow cytometry confirmed that SIRT5 inhibition significantly counteracted histidine and 6-MP-mediated disease control and enhanced the human CD19+ leukemia frequencies in the peripheral blood, bone marrow, and spleen.